AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2003 OCT 1 - (NewsRx.com & NewsRx.net) -- T-cell reactivity to amyloid beta increases with age in many people and may open avenues of therapeutic and preventive treatments for Alzheimer disease.
According to published research from the United States, "Alzheimer disease (AD) is characterized by the progressive accumulation of amyloid beta protein (A-beta) in areas of the brain serving cognitive functions such as memory and language. The first of two separate reports reveals that intrinsic T-cell reactivity to the self-antigen A-beta exists in many humans and increases with age. This finding has implications for the design of A-beta vaccines."
"The second report demonstrates that a number of FDA-approved nonsteroidal anti-inflammatory drugs are capable of lowering A-beta levels in mice," wrote John R. Cirrito and David M. Holtzman at Washington University at Washington University in St. Louis. "The work suggests that further testing of the therapeutic utility of these ...